Staff View: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer

Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer

Triple-negative breast cancer (TNBC) constitutes a very aggressive type of breast cancer with few options of cytotoxic chemotherapy available for them. A chemotherapy regimen comprising of doxorubicin hydrochloride and cyclophosphamide, followed by paclitaxel, known as AC-T, is approved for usage as...

Full description

Main Authors:	Guido, Bruna Cândido, Brandão, Douglas Cardoso, Barbosa, Ana Luisa Augusto, Vianna, Monique Jacob Xavier, Faro, Lucas, Ramos, Luciana Machado, Nihi, Fabíola, Castro, Márcio Botelho de, Neto, Brenno A. D., Corrêa, José Raimundo, Báo, Sônia Nair
Format:	Artigo
Language:	Inglês
Published:	Oncotarget 2021
Subjects:	Mamas - câncer Mamas - câncer - tratamento
Online Access:	https://repositorio.unb.br/handle/10482/42548 https://doi.org/10.18632/oncotarget.28068
Tags:	Add Tag No Tags, Be the first to tag this record!

id	ir-10482-42548
recordtype	dspace
spelling	ir-10482-425482021-12-07T16:40:06Z Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer Guido, Bruna Cândido Brandão, Douglas Cardoso Barbosa, Ana Luisa Augusto Vianna, Monique Jacob Xavier Faro, Lucas Ramos, Luciana Machado Nihi, Fabíola Castro, Márcio Botelho de Neto, Brenno A. D. Corrêa, José Raimundo Báo, Sônia Nair Mamas - câncer Mamas - câncer - tratamento Triple-negative breast cancer (TNBC) constitutes a very aggressive type of breast cancer with few options of cytotoxic chemotherapy available for them. A chemotherapy regimen comprising of doxorubicin hydrochloride and cyclophosphamide, followed by paclitaxel, known as AC-T, is approved for usage as an adjuvant treatment for this type of breast cancer. In this study we aimed to elucidate the role of KIF11 in TNBC progression throughout its inhibition by two synthetic small molecules containing the DHPM core (dihydropyrimidin-2(1H)-ones or -thiones), with the hypothesis that these inhibitors could be an interesting option of antimitotic drug used alone or as adjuvant therapy in association with AC. For this purpose, we evaluated the efficacy of DHPMs used as monotherapy or in combination with doxorubicin and cyclophosphamide, in Balbc-nude mice bearing breast cancer induced by MDA-MB-231, having AC-T as positive control. Our data provide extensive evidence to demonstrate that KIF11 inhibitors showed pronounced antitumor activity, acting in key points of tumorigenesis and cancer progression in in vivo xenograft model of triple negative breast cancer, like down-regulation of KIF11 and ALDH1-A1. Moreover, they didn’t show the classic peripheral neuropathy characterized by impaired mobility, as it is common with paclitaxel use. These results suggest that the use of a MAP inhibitor in breast cancer regimen treatment could be a promising strategy to keep antitumoral activity reducing the side effects. 2021-12-07T16:40:06Z 2021-12-07T16:40:06Z 2021-09-14 Artigo GUIDO, Bruna Cândido et al. Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer. Oncotarget, v. 12, p. 1920-1936, 2021. DOI: https://doi.org/10.18632/oncotarget.28068. Disponível em: https://www.oncotarget.com/article/28068/text/. Acesso em: 07 dez. 2021. https://repositorio.unb.br/handle/10482/42548 https://doi.org/10.18632/oncotarget.28068 Inglês Acesso Aberto Copyright: © 2021 Guido et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. application/pdf Oncotarget
institution	REPOSITORIO UNB
collection	REPOSITORIO UNB
language	Inglês
topic	Mamas - câncer Mamas - câncer - tratamento
spellingShingle	Mamas - câncer Mamas - câncer - tratamento Guido, Bruna Cândido Brandão, Douglas Cardoso Barbosa, Ana Luisa Augusto Vianna, Monique Jacob Xavier Faro, Lucas Ramos, Luciana Machado Nihi, Fabíola Castro, Márcio Botelho de Neto, Brenno A. D. Corrêa, José Raimundo Báo, Sônia Nair Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
description	Triple-negative breast cancer (TNBC) constitutes a very aggressive type of breast cancer with few options of cytotoxic chemotherapy available for them. A chemotherapy regimen comprising of doxorubicin hydrochloride and cyclophosphamide, followed by paclitaxel, known as AC-T, is approved for usage as an adjuvant treatment for this type of breast cancer. In this study we aimed to elucidate the role of KIF11 in TNBC progression throughout its inhibition by two synthetic small molecules containing the DHPM core (dihydropyrimidin-2(1H)-ones or -thiones), with the hypothesis that these inhibitors could be an interesting option of antimitotic drug used alone or as adjuvant therapy in association with AC. For this purpose, we evaluated the efficacy of DHPMs used as monotherapy or in combination with doxorubicin and cyclophosphamide, in Balbc-nude mice bearing breast cancer induced by MDA-MB-231, having AC-T as positive control. Our data provide extensive evidence to demonstrate that KIF11 inhibitors showed pronounced antitumor activity, acting in key points of tumorigenesis and cancer progression in in vivo xenograft model of triple negative breast cancer, like down-regulation of KIF11 and ALDH1-A1. Moreover, they didn’t show the classic peripheral neuropathy characterized by impaired mobility, as it is common with paclitaxel use. These results suggest that the use of a MAP inhibitor in breast cancer regimen treatment could be a promising strategy to keep antitumoral activity reducing the side effects.
format	Artigo
author	Guido, Bruna Cândido Brandão, Douglas Cardoso Barbosa, Ana Luisa Augusto Vianna, Monique Jacob Xavier Faro, Lucas Ramos, Luciana Machado Nihi, Fabíola Castro, Márcio Botelho de Neto, Brenno A. D. Corrêa, José Raimundo Báo, Sônia Nair
author_sort	Guido, Bruna Cândido
title	Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
title_short	Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
title_full	Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
title_fullStr	Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
title_full_unstemmed	Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
title_sort	exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
publisher	Oncotarget
publishDate	2021
url	https://repositorio.unb.br/handle/10482/42548 https://doi.org/10.18632/oncotarget.28068
_version_	1721216744218951680
score	13.657419

Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer

Similar Items